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Abstract 
Problem: The CDC estimates one person every 20 minutes every day acquires an HPV-
related cancer.  Kentucky’s HPV associated cancer burden is among the highest in the nation.  
Adolescent HPV vaccination rates in Kentucky are far below HealthyPeople 2020 goals. Barriers 
are multifaceted and include provider, patient and system barriers. The AFIX model is an 
evidenced based quality improvement program that addresses key provider barriers. The USPSTF 
findings identify a gap in the literature related to AFIX methods to improve rates of adolescent 
vaccines.  
Objectives: The purpose of this study was to evaluate the effects of an intervention using 
the AFIX model and provider education focusing on the HPV vaccine as cancer prevention. Goal: 
To evaluate provider knowledge & attitudes of the HPV vaccine and evaluate the effects of 
provider education on vaccine rates.  Specific Aims: 1. Evaluate frequency of use of CDC Talking 
Points (rubric) 2. Evaluate changes in vaccination with use of rubric.  
Methods:  Utilizing the Assessment Feedback Incentives eXchange (AFIX) model, this 
quasi-experimental pilot research project included four phases: a retrospective chart review to 
establish baseline rates of HPV vaccination and a provider survey to identify barriers and 
facilitators (Phase 1), an educational intervention focused on presenting the HPV vaccine as 
cancer prevention (Phase 2), a process/outcome evaluation (Phase 3&4) to assess use and 
feasibility of the CDC talking points rubric and an outcome evaluation to assess any change in 
vaccine uptake. 
Primary outcome variable: adolescents age 11-17, with no prior history of the HPV 
vaccine receiving at least one dose.  
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Results: 63 of 100 medical records reviewed met inclusion criteria.  79% of adolescents 
received one dose of the HPV vaccine at a well-child visit. Only 34% received dose 2, and only 
8% received dose 3.  Significant demographic findings: older adolescents and non-Hispanics were 
less likely to initiate HPV vaccine. Provider survey results revealed the most commonly reported 
barrier at 80% was the HPV vaccine not being required for school entry. Participation in the 
Vaccines for children (VFC) program was the most commonly reported facilitator at 82%. The 
post-intervention process evaluation revealed 50% of the providers changed the way they 
presented the HPV vaccine to parents.  None of the providers used the CDC rubric and the most 
common barrier was not having a copy to refer to.  Two-thirds of the providers felt uptake of the 
vaccine had increased since the 2-dose series introduced.  Only 83% offer vaccine to females & 
males 100% of the time.  None of the providers feel the vaccine is accepted 100% of the time.  
Summary/Implications:  At 79%, the proportion of adolescents at HealthFirst Bluegrass 
age 11-17 with one dose of the HPV vaccine was above the statewide average of 58%.  The 
proportion with 2 and 3 doses were on par with national averages, but were still below 
benchmark. Because the baseline rates were just below the 80% goal and the provider surveys 
revealed the school requirement barrier, the PI chose to shift the focus to a policy intervention at 
the school level.  Using a CDC drafted school nurse letter to parents of adolescents, the PI 
proposed a new version of the 5
th
 grade letter to be sent to all Fayette county incoming middle 
school students.  The current letter only lists the 2 state required vaccines (Tdap, MCV) and not 
the third ACIP recommended HPV vaccine.  Given the recent change in the ACIP 
recommendation to a 2-dose regimen for young teens, this provides a prime opportunity to 
promote the HPV vaccine to Fayette county middle school students and their parents.   
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Use of the AFIX Model to Improve Adolescent HPV Vaccination: 
A Pilot Research Project  
Introduction 
Rates of Human Papillomavirus (HPV) vaccination in Kentucky (KY) are below the 
national average.  Because of the identified link between provider recommendation and increased 
rates of HPV vaccination (Smith, Stokley, Bednarczyk, Orenstein, & Omer, 2016), provider-
based  interventions such as the successful Assessment, Feedback, Incentives and Exchange 
(AFIX) program should be implemented at the local level. AFIX is a quality improvement 
program used to raise immunization coverage levels, reduce missed opportunities to vaccinate, 
and improve standards of practice at the provider level (Centers for Disease Control & 
Prevention, 2015). The AFIX program is an evidence-based intervention developed by the 
Centers for Disease Control and Prevention (CDC) which gained recognition after immunization 
coverage levels in public clinics in Georgia increased from 40% to 91% between 1986 and 2001. 
Since 1996, this intervention has become a national model program to improve immunization 
rates (LeBaron et al., 1997). The Community Preventive Services Task Force (CPSTF), a branch 
of the United States Department of Health and Human Services (US-DHHS), “strongly 
recommended” assessment and feedback methods such as AFIX in 1999, 2008, and 2015.  The 
task force’s regularly updated systematic review of the literature supports the use of the AFIX 
model.  Specific gaps in the literature identified by the CPSTF include measuring the 
effectiveness of the AFIX program on adolescent vaccines (CPSTF, 2015). This provides 
additional support for this pilot practice improvement project.   
The following manuscript will include background information on both the HPV disease 
epidemiology and the historical rates of the HPV vaccine.  Additionally, a summary of a focused 
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integrative literature review provided the evidence base for the chosen AFIX design and the 
methods of this pilot research project.    The overall objectives and specific aims of the study 
were based on HealthyPeople 2020 and 2016 Healthcare Effectiveness Data and Information Set 
(HEDIS) measures for the HPV vaccine.  The phases of methodology include a retrospective 
chart audit, a baseline provider survey and educational intervention, and an outcome evaluation.  
Specific study barriers and facilitators will follow the chart audit results and data analysis.   
Finally, the practice and policy implications and areas for future research will conclude the 
manuscript. 
Background 
 According to the CDC, nearly 39,000 HPV associated cancers occur annually.  
Approximately 23,000 cases are women and 19,000 are men. Of the HPV-associated cancers, 
cervical cancer is the most prevalent in women, and oropharyngeal cancers are the most prevalent 
in men.  Nearly 90% of cervical and anal cancers, 70% of oropharyngeal, vaginal and vulvar 
cancers, and 60% of penile cancers are HPV associated (CDC, 2016).  The direct link between 
HPV and cancer led to the development of the Human Papillomavirus Quadrivalent (Types 6, 11, 
16, 18) Vaccine, Recombinant, approved in 2006.  Additionally the Human Papillomavirus 
Bivalent (Types 16 and 18) Vaccine, Recombinant was approved in 2009, and the Human 
Papillomavirus 9-valent Vaccine, Recombinant was approved in 2014 (U.S. Food & Drug 
Administration, 2016).  
Kentucky has some of the highest rates of HPV associated cancers in the United States.  
Specifically, Kentucky’s oropharyngeal cancer incidence rates rank first in men and third in 
women.  Vaginal and vulvar cancer incidences in KY rank first and second, respectively.  Penile 
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cancer incidence in Kentucky is second highest in the nation.  Lastly, among the most common 
HPV related cancer, cervical, Kentucky ranks 7th highest in incidence (CDC, 2016).  Primary 
prevention methods such as the HPV vaccine can reduce this disease burden. 
In 2006, the HPV vaccine was approved by the U.S. Food and Drug Administration 
(FDA) and the national Advisory Committee on Immunization Practices (ACIP) recommended 
the vaccine be administered to females age 11-24. The HPV vaccine originally approved was a 
three dose series with doses at zero, two, and six month intervals.  In 2009, the vaccine was 
further approved and recommended for administration to adolescent males age 9-26.  Most 
recently in October of 2016, the Quadrivalent and 9-valent vaccines were approved for a reduced 
two- dose series with the second dose administered six to twelve months after dose one.   
Since 2006, the uptake and compliance rates in adolescents have increased slowly, but the 
vaccines continue to be underutilized.  HPV continues to have lower uptake than the Tetanus-
Diptheria-Pertussis (Tdap) and Meningicoccal vaccines (MCV).  NIS-teen data from 2015 reveal 
that Kentucky ranks 32
nd
 in the nation in Tdap rates with 84% of adolescents age 13-17 with > 1 
dose Tdap, 22
nd
 in the nation in MCV rates with 79% with > 1 dose MCV, and only 57.4% of 
females and 34.8 % males with > 1 dose HPV. Additionally, the most recent CDC NIS-teen data,  
released in August of 2016 reveals that Kentucky ranked 47
th
 of 50 states for 2015 in completion 
of the series or > 3 doses of HPV vaccination in males, with a rate of only 17.1%. Females with > 
3 doses are nearly double at 36.2%, and with > 2 doses 42.7% (Reagan-Steiner et al., 2016). The 
disparity between rates of Tdap, MCV and HPV reveal missed clinical opportunities since all 
three can be given at the same 11-12 year old well child visit.   Methods to increase the uptake of 
the HPV vaccine have been reported in the literature.    
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Evidence base for Intervention 
 The AFIX program has its roots in the public health clinics of Georgia. In order to 
increase coverage levels to achieve national immunization goals, the Georgia Department of 
Public Health initiated a statewide program in 1986 that consisted of annual assessments of 
immunization records at its public health clinics.  Feedback was given to clinic providers and 
their staff who then devised their own interventions to improve vaccination rates.  Program 
incentives included awards and rankings of clinics by coverage level as well as poster 
presentations by successful clinics at annual immunization meetings. Other successful strategies 
included coordinating with Women, Infants, and Children (WIC) Food and Nutrition Service, 
conducting reminder/recall phone activities, and providing performance feedback to nursing 
staff.  Resulting from these combined efforts were immunization coverage levels in Georgia 
public clinics increasing from 40% to 91% between 1986 and 2001. This intervention has 
become a national model program to improve immunization rates (CDC, 2014).   
 LeBaron (1997) sought to investigate the marked increase in vaccination rates noted over 
an 8-year period.  He investigated the methods used and the outcomes to compare to national 
averages.  From 1988 – 1994 LeBaron was able to show that while Georgia’s vaccination rates 
rose from 53% to 89%, the national average from the National Health Interview Survey (NHIS) 
database rose from 53% to only 60% showing that the AFIX intervention was effective.  The 
CDC chose to adopt the Georgia model and recommend its use to all states.  In 1999, LeBaron 
expanded his research further to include other states and cities using the AFIX model.  He was 
able to show in four states (Colorado, Iowa, Louisiana and Missouri) and two large cities 
(Boston and Houston) how use of the AFIX model led to vaccine rate improvements on par with 
Georgia at five percentage points per year or a total average increase of 20% over four years.   
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Appraisal of Evidence 
 Over the past several years as the focus on low rates of HPV vaccination has increased, a 
few studies correlating the AFIX model with adolescent vaccine rates have been conducted.   
An appraisal of the evidence was performed by compiling a synthesis table of the studies (see 
Table 2). These studies were important in elucidating the need for the proposed provider AFIX 
intervention. Common provider identified barriers such as time to educate, parental resistance 
and difficulty in discussing HPV as an STI were identified in four of the studies (Bruno et 
al.,2014; Bynum et al., 2014;  Ferrer, H., Trotter, C., Hickman, M., & Audrey, S. , 2014; Hull et 
al., 2014).  Perhaps the strongest evidence was the common theme of provider as facilitator in 
two of the level 1 studies (Jeudin et al., 2014; Rambout et al., 2014) and two other level 4 and 5 
studies (Reiter et al., 2014; Thomas, Strickland, Diclemente, & Higgins, 2013).  Lastly, there is 
sufficient evidence supporting the use of the AFIX model to improve rates of adolescent HPV 
vaccination.  Five total studies ranging from levels 2-7 all show statistically significant rate 
changes after implementation of an AFIX model at the provider level (Gilkey, Moss, et al., 2014; 
LeBaron et al., 1997; LeBaron et al., 1999a; Moss, Reiter, Dayton, & Brewer, 2012a;Perkins et 
al. ,2015) (see Table 2).    
 Based on a review of the available literature, there is evidence to suggest that 
implementation of provider interventions, such as the AFIX model, could improve uptake of the 
HPV vaccine in adolescents.  Part of the HealthyPeople 2020 goals is to have at least 50% of 
both public and private vaccine providers implement a method to measure their vaccination 
coverage.  The public sector is mandated to do this because they receive funds or vaccine 
directly from the government.  Vaccines for children (VFC) providers have mandated visits with 
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Comprehensive Clinic Assessment Software Application (CoCASA) reports with rates of 
immunization used as feedback.  
Purpose 
 The purpose of this project was to evaluate the impact of a provider-focused educational 
intervention focusing on HPV vaccine as cancer prevention.  Primary outcome variables were 1) 
adolescents age 11-17 with no prior history of the HPV vaccine initiating the vaccine at a well-
child visit and 2) proportion of providers utilizing the CDC Talking Points.    
This pilot research project was conducted at an urban health clinic in the southern United States. 
The specific goal of the project was to increase rates of HPV vaccination among adolescents at 
the clinics through provider education and use of the AFIX quality improvement model. Specific 
Aims: 1. Evaluate frequency of use of CDC Talking Points (rubric) 2. Evaluate changes in 
vaccination with use of rubric. Hypothesis: 1. Educational session will increase use of rubric 
from 0 to 80% 2. Use of the rubric will increase initiation rates to 80%.   
This pilot research project aimed to assist a Health Resources and Services Administration 
(HRSA) granted primary care organization in the Southeast.  Improving rates of adolescent HPV 
vaccination could fulfill the HealthyPeople 2020 goal of 80% vaccination rates among 
adolescents.  Quality improvement measures such as improving vaccine rates help to fulfill 
requirements of HRSA grantees. 
Methods/Study Design 
This quasi-experimental pilot research project design included four phases: a retrospective 
chart review (Phase 1), an educational intervention (Phase 2), a process evaluation (Phase 3), and 
an outcome evaluation (Phase 4).   
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The retrospective chart review was conducted on patient charts from December 15, 2015 
to February 15, 2016. Additionally, a post-intervention retrospective chart review was planned 
from December 15, 2016 to February 15, 2017. All providers volunteering to participate in the 
face-to-face educational in-service signed an informed consent prior to participation. The HPV 
vaccine is ACIP recommended at the 11-12 year old well child visit or on a catch-up schedule.  
Based on a power analysis of increasing rates from 57% to 80%, the goal was to review at least 
100 medical records.  The data collected during the chart review included patient age, gender, 
race, and insurance type.  Other data included was if counseling on the vaccine was provided and 
by whom, if the vaccine was offered, if it was accepted/declined/deferred by the patient, if the 
series was initiated, and if it was completed.  No patient identifying information was included. 
All pediatric and family providers practicing in the clinic were asked to participate in the 
survey and educational session.  An email with a survey cover letter was sent to all providers in 
the clinic. The survey was administered via REDCap, and all survey results were kept 
anonymous.  For the educational session, the PI asked for volunteers and distributed informed 
consents at a provider staff meeting prior to the scheduled educational session.  Participation in 
the educational session was also voluntary. 
Research Procedures 
  For the retrospective chart review, the PI assessed the FQHC clinic practices regarding 
HPV vaccine rates. Specifically, the PI examined 100 electronic medical records to assess the 
proportion of HPV vaccines that were administered to adolescents between 11-17 years of age.  
The clinic provided a list of patient medical record numbers for patients ages 11-17 that 
presented to the FQHC clinic for routine well-child exams (V20.2) between December 15, 2015 
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and February15, 2016.  No one other than the PI had access to the list of medical record 
numbers, and the list was kept in a locked file cabinet drawer in the clinic.  Only the PI had this 
key.  Once the electronic medical records were accessed, the list of medical record numbers was 
destroyed per the clinic’s HIPAA policy.  Participants included all males and females age 11-17 
with encounter for a well-child visit with vaccines (ICD-9 codes V20.2, V04.89, V05.8 and CPT 
code 90649).  Patients were excluded if they initiated the HPV vaccine before the current 11-17 
year old well-child visit. 
Survey/ Educational Intervention 
Before initiating the educational phase, an online REDcap survey and cover letter on the 
HPV vaccine was distributed to all pediatric providers at the clinic via email. An educational 
session on the CDC Talking Points evidence based rubric was presented at several lunchtime 
staff meetings to those providers volunteering to participate between December 1
st
 and 15
th
 and 
completing the informed consent.  This educational session was part of the Incentives component 
of the AFIX program.  Providers were then asked to trial use of the CDC script in their 
adolescent visits. 
Process/Outcome Evaluation  
To determine feasibility and sustainability of the intervention, anonymous provider 
surveys sent via REDcap were completed voluntarily two months after the intervention 
(educational session).  Providers were asked to report on whether they are using the CDC talking 
points, and if so, how often; if not, they were asked to disclose the barriers (see Appendix G). 
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The final planned step of this pilot research project was a measurement of the proportion 
of HPV vaccination rates in 11-17 year olds two months after the intervention. This was to be 
completed using the same electronic medical record review process and inclusion/exclusion 
criteria to determine baseline rates of HPV vaccination. One hundred to 200 medical records 
were originally proposed for the outcome evaluation from December 15, 2016- February 15, 
2017.  The quantity of records (100-200) was based on the original power analysis to increase 
the proportion from 57% to 80%.  Because the baseline rates were 79%, a revised power analysis 
indicated that 600 records would be needed to detect a significant change in vaccine rates given 
the goal of 80%.  In two months time 600 well visits for 11-17 year olds would not be generated. 
Therefore, the outcome evaluation of vaccine rates was not completed. 
Data collection/analysis 
 All data was collected in Redcap, a secure online research database.  The database was  
analyzed using statistical SPSS software version 23.0 using crosstabs with frequencies, 
percentages and chi-squared analysis.  Significant findings were reported at p  > .05. 
Results 
Retrospective medical record review of 100 electronic medical records revealed the 
following descriptive data:  63 met inclusion criteria of no prior history of the HPV vaccine; 
79% (n=50) initiated/accepted the HPV vaccine; only 34% (n=17) received the 2
nd
 dose, and 
only 8% (n=4) completed the series with the third dose.  Uptake of the HPV vaccine was broken 
down into the following demographic categories: age, gender, race, ethnicity and insurance 
coverage (see Table 1).  Significant findings included age and ethnicity.  Adolescents accepting 
the HPV vaccine were significantly younger than those who declined to initiate vaccination 
(M=13.1, SD=2.0 versus M=14.5, SD=2.1; p =.024).  Non-Hispanics (69%) were significantly 
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less likely (p=0.012) to initiate the HPV vaccine compared with Hispanics (92%). Gender, race 
and insurance status were non-significant. 
 Baseline surveys were distributed to 14 pediatric providers, and 11 providers 
participated.  Questions were posed related to the provider practice of offering the HPV vaccine 
and provider perception of HPV vaccine uptake.  Additional survey questions evaluated provider 
identified barriers and facilitators to uptake.   
A majority of providers or 63% (n=7) report offering the HPV vaccine 100% of the time 
to females and males, 27% (n=3) offer females and males the vaccine 75-99% of the time, and 
just 10% (n=1) offer it 50-74% of the time.   Provider perception of vaccine uptake by gender 
was more varied.  Only 27% (n=3) of providers reported that females initiated HPV vaccine 75-
99% of the time, whereas the remaining 73% (n=8) reported female uptake as 50-74%.  Male 
uptake of the vaccine was reported as lower, with only 27% (n=3) reporting 75-99%, 44% (n=5) 
reporting 50-74%, 18% (n=2) reporting 25-49%, and <10% (n=1) reporting 0-24% of male 
uptake (see Tables 2-5).    
The most commonly reported barrier by just over 80% (n=8) of providers was not having 
the HPV vaccine as a requirement for middle school entry.  Most frequent provider reported 
facilitators were participating in the VFC program 82% (n=9) and having the time to educate 
patients about the HPV vaccine 73% (n=8).   
  Provider survey results revealed that 50% of providers (n=3) changed the way they 
presented the vaccine, although none of them reported using the CDC Talking Tips.  The most 
commonly reported barrier was not having a copy of the CDC Talking Tips available.  Lastly, as 
discussed previously, the outcome evaluation of a change in vaccine rates was not completed due 
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to baseline proportion of 79% with a power analysis of > 600 EMRs needed to detect a 
statistically significant change to the goal of 80%.   
Discussion 
Major findings 
The retrospective record review revealed that 79% of the FQHC’s adolescents age 11-17 
with no prior history of the HPV vaccine initiated/accepted the vaccine at a well-child visit.  This 
was just below the goal of 80% based on HealthyPeople 2020 goals.  Uptake of doses 2 and 3 
were significantly lower at 34% and 8% respectively. Significant demographic correlations 
included both age and ethnicity. The younger the patient the more likely they were to accept dose 
1 of the HPV vaccine. This finding is potentially based on the increase in well child visits at age 
11-12 for adolescents to get the school required physical and Tdap and MCV immunizations.  
This study’s results are different from Bynum et al. (2014) and Reiter et al. (2014) who found 
that older adolescents age 13-14 were more likely to initiate the vaccine. Additionally, Hispanic 
patients were more likely to accept /initiate the vaccine than non-Hispanic patients.  This mirrors 
the 2015 NIS-teen data revealing Hispanic males & females having higher uptake of the HPV 
vaccine over non-Hispanics (CDC, 2016).   Baseline provider survey results highlighted the 
barrier of the HPV vaccine not being required for school entry, as well as providers being less 
likely to offer the vaccine to males over females.  The post-intervention survey revealed that 
50% of respondents (n=6) changed the way they present the HPV vaccine to patients.  None of 
the providers used the CDC rubric specifically, and the most commonly reported barrier to this 
was not having a copy of the rubric available.   
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Study Barriers/Facilitators 
  Barriers encountered were mostly logistical in nature.  Initially, the PI planned to have an 
educational session (the study intervention) for all pediatric providers at one or two staff 
meetings.  The pediatric providers work at two main clinics and seven school-based clinics.  This 
group only meets every other month, and the adult providers (not part of the study population) 
are also at those meetings.  Additionally, as part of an accreditation process, this FQHC had an 
Operational Site Visit (OSV) scheduled in early December, so all staff meetings for the month 
were cancelled.   
Consequently, the intervention phase was several either individual or small group 
meetings to present the CDC Talking Points rubric.  This shift in methodology actually became a 
facilitator because of the small group or individual environment.  Several of the providers were 
able to verbalize their frustrations at the HPV vaccine not being required for school entry as a 
significant barrier to the vaccine’s uptake.  Additionally, the PI was able to review the new 
Vaccine Information Statement (VIS) with the 2-dose ACIP regimen just released December 2
nd
, 
2016.  A few providers were unaware of the 2-dose series until it was presented.   The providers 
at the seven school based clinics were also not together for a meeting during the proposed 
educational phase of the study.  Several, but not all, of the school based pediatric providers 
completed the online survey.  Rather than a face to face educational intervention, the PI 
distributed the CDC Talking Points rubric and the CDC slide-set to the seven school based 
providers via email as they were not available in the last two weeks of December because of 
School Clinic closings.    
Other facilitators of this pilot study were guideline based and patient education/ outreach 
based.  At the time of the study intervention (mid-December), the new CDC/ ACIP 
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recommendation for a 2-dose regimen for 11-15 year olds was released.   The new VIS, dated 
12/2/2016, was distributed to providers and nurses, but practice dissemination had not yet 
occurred.  This provided an additional incentive for the PI to encourage providers to recommend 
the new 2-dose HPV series to adolescents.  Additionally, the VFC program distributed large, 
stand-up life size posters of a boy and a girl with the logo “If there were a vaccine against cancer 
wouldn’t you give it to me?”  At the time of the provider intervention, the two main clinics of the 
FQHC had these life-size posters in their lobbies. Only one of the school clinics had the posters 
displayed.   
Practice Implications 
Based on the results of the medical record review and provider survey, several practice 
and policy recommendations can be made. Specifically, the provider survey highlighted the 
perception that males initiate the HPV vaccine less often than females.  Implications include the  
need to make a concerted effort targeting males especially since their rates of cancer are 
comparable (CDC, 2016).  This perception could lead to providers’ hesitation to strongly 
recommend the HPV vaccine to males as well as females.  The objective data from the 
retrospective record review revealed that males had a slightly higher uptake over females, 
possibly suggesting recommendation to females should be stronger.  Other demographic data 
that could influence practice habits relate to ethnicity and insurance status.  Non-Hispanics and 
those with Medicaid or no insurance were less likely to initiate the vaccine.  The latter group is 
the population eligible for free vaccine from the VFC program.  According to the provider 
survey of patient facilitators, awareness of the VFC program ranked lowest with only 36% (n=4) 
of providers believing their patients were aware of the availability of free vaccines.  This 
combination of data indicates a practice gap for promoting patient awareness of the VFC 
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program.  Another possible area for practice change is EMR prompts or reminders.  Only one 
provider indicated that EMR prompts/ reminders influenced HPV vaccine rates.   
  Upon review of patients missing the HPV vaccination, a check of the Kentucky 
Immunization Registry (KYIR) found several records of either HPV vaccine initiation or 
completion.  These records had not been either scanned into the EMR or manually entered as 
historical into the immunization record.  A process recommendation to the clinic manager, 
CMAs and nurses will be that a designated person check the KYIR weekly for all scheduled well 
child visits to ensure up to date records.  
Policy Implications 
According to Bynum et al. (2014) survey results of provider-identified barriers can be 
utilized in development of interventions to increase vaccination rates.  The provider survey 
results from this study reveal that the lack of a school mandate is a significant barrier.  Efforts 
nationwide to school mandate the HPV vaccine have been poorly received.  Unfortunately, in 
Kentucky there have been several failed legislative attempts for HPV vaccine education or a 
school mandate for adolescents to obtain the HPV vaccine (National Council of State 
Legislatures, 2017).  To date, only two states and the District of Columbia have a school 
mandate for the HPV vaccine.  While legislation mandating this may not be realistic at this point, 
an alternate strategy would be to include an endorsement by both the school nurses and 
principals on the school letters sent home to all incoming middle school students.   The CDC as 
well as the National Association of School Nurses (NASN) have the same adolescent vaccine 
letter template (see Appendix F) posted as a policy initiative for school districts (CDC, 2016; 
National Association for School Nurses, 2015).  The PI proposed that this letter replace the 
USE OF THE AFIX MODEL TO IMPROVE ADOLESCENT HPV 
 
17 
 
current school letter distributed to all rising 6
th
 graders.   The letter currently in use only lists the 
two adolescent vaccines required by Kentucky Statute (Tdap and MCV), but omits the 
CDC/ACIP recommended HPV vaccine.  A key component of the proposed letter is the focus of 
the HPV vaccine as cancer prevention.  Additional strength to this letter will be the new 2-dose 
regimen CDC/ACIP approved December 2, 2016 for adolescents age 11-15.   The PI amended 
the CDC letter to include the 2-dose regimen, as the online school letter template did not reflect 
this change.  This letter was proposed to the school district health coordinator in a meeting on 
February 23, 2017.  The district health coordinator approved the nurse and principal letter for 
distribution this spring and summer to all incoming middle school students. 
Summary 
 The burden of HPV associated cancers in Kentucky is among the highest in the country.    
Additionally, the rates of HPV vaccination continue to be far below the nationwide averages.  
Although Kentucky’s initiation rates are low, this pilot study revealed an FQHC with initiation 
rates near HealthyPeople 2020 goals.   Provider identified barriers and facilitators influenced the 
practice and policy implications. The most commonly reported barriers at just over 80% (n=9) 
were the lack of a school mandate for the HPV vaccine and the fact that patients are unlikely to 
return for doses 2 and 3.   Objective data supported the providers’ subjective data as only 34% of 
patients returned for dose 2 and only 8% for dose 3.  Based on this, a policy initiative to increase 
all three ACIP adolescent vaccines was proposed to the Fayette county district health coordinator 
in late February.  A nurse letter, principal letter and text message reminders for all 3 ACIP 
recommended adolescent vaccines will be initiated this spring. 
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Future research could assess the impact of the school based campaign as well as the new 
2-dose series.  Because of the provider reported barrier of returning for doses 2 and 3, a follow-
up study at the FQHC could include an assessment of completion rates with the new 2-dose 
regimen versus completion rates with the 3-dose regimen.   
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Table 1. Demographic characteristics by HPV vaccination (N=63) 
 Total sample 
 
 
n = 63 
Initiated HPV vaccination  
p 
Yes 
(n =50) 
No 
(n =13) 
 
Age  13.1 (2.0) 14.5 (2.1) .024* 
Sex 
   Male 
   Female 
     
 
29 (54%) 
34 (46%) 
  
22 (72%)  
28 (84%)  
 
7 (18%) 
6 (22%) 
 
 
>.05 
Race 
   White 
   Black 
   Other 
 
19 (30%) 
37 (60%) 
6  (10%) 
 
14 (74%) 
32 (87%) 
3 (50%) 
 
5 (26%) 
5 (13%) 
3 (50%) 
 
>.05 
Ethnicity 
   Hispanic 
   Non-Hispanic 
 
39 (62%) 
24 (38%) 
 
27 (69%) 
23 (92%) 
 
12 (31%) 
1 (8%) 
 
.012* 
Insurance 
Private 
Medicaid 
Uninsured  
 
5 
46 
11 
 
5  (100%) 
36 (78%) 
9   (82%) 
 
0  (0%) 
10 (22%) 
2   (18%) 
 
>.05 
*significance at level p <.05  
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Table 2.  Provider Survey Results (n=11) offer vs. accept/initiate HPV vaccine 
 
100% 75-99% 50-74% 25-49% 
How often offer HPV vaccine to females 11-17 7 3 1 0 
How often offer HPV vaccine to males age 11-17 7 3 1 0 
How often do females accept/initiate 0 3 8 0 
How often do males accept/initiate 0 3 5 2 
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Table 3.  Provider reported practice facilitators (n=11) 
Practice facilitators 
 
Total 
Participates in the VFC program 9 11 
Have the time to educate patients about the HPV vaccine 8 11 
Reminders within the EMR for the HPV vaccine 1 11 
Clinic uses a form that prompts CDC recommended vaccines 2 11 
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Table 4. Provider reported practice barriers (n=11) 
 Yes  Total 
I do not have the time to discuss HPV vaccination  
during visits 
2 11 
Practice not adequately reimbursed for HPV vaccine 1 11 
HPV vaccine not stocked or in low supply 0 11 
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Table 5. Provider reported patient barriers (n=11) 
Unaware of the risks of HPV 4 11 
Think the cost of the HPV vaccine is too high 0 11 
Worried about long-term safety of the vaccine 0 11 
Unlikely to return for 2nd and 3rd dose 7 11 
Unlikely to get vaccine because it is not required for 
school entry 
8 11 
Concerned about the pain associated with the vaccine 1 11 
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Table 6. Relevant literature 
Citation Conceptu
al 
Framewo
rk 
Design/ 
Method 
Sample/Settin
g 
Major 
Variables 
Studied and 
Their 
Definitions 
Outcome 
Measureme
nt 
Data 
Analysis 
Findings Level 
of 
Evid
ence 
Quality of 
Evidence: 
Critical 
Worth to 
Practice 
(Ferrer 
et al., 
2014) 
Ferrer, 
H. B., 
Trotter, 
C., 
Hickma
n, M., & 
Audrey, 
S. 
(2014). 
Barriers 
and 
facilitat
ors to 
HPV 
vaccinat
ion of 
young 
women 
in high-
income 
countrie
s: a 
qualitati
Critical 
Appraisal 
Skills 
Program
me 
criteria 
for 
evaluatin
g 
qualitativ
e research 
Qualitati
ve 
systemati
c review 
and 
evidence 
synthesis 
 
 
Sample:  41 
Studies were 
eligible if 
qualitative 
research 
methods 
(interviews, 
focus groups, 
observations) 
or open-ended 
questions in 
questionnaires 
were used to 
explore views 
and behaviors 
related to 
decision-
making of 
HPV 
vaccination of 
young women. 
Qualitative 
& 
descriptive,  
so no 
independent/ 
dependent 
variables 
quantified 
Used a socio-
ecological 
model to 
provide a 
framework 
for 
understandin
g how 
decisions of 
stakeholders 
at different 
levels of the 
model may 
affect access 
of the HPV 
vaccine for 
young 
women. 
Data 
pertaining to 
the 
methodology 
and context, 
including 
study and 
participant 
characteristic
s of each 
primary 
study, were 
extracted and 
entered into 
an excel 
spread sheet 
by one 
reviewer 
(HF). 
Qualitative 
findings: 
providers were 
generally 
favorable 
towards  HPV 
vaccine; some 
felt 
uncertainty 
about 
 the safety 
profile of the 
vaccine and 
that early 
vaccination 
may mean 
protection 
would not be 
maintained to 
the age of 
sexual debut; 
Healthcare 
professionals 
suggested that 
parents with 
general ‘anti-
V Strengths:  
Comprehensi
ve review of 
a range of 
perspectives 
resulting in a 
more 
complete 
picture in 
relation to 
decision-
making for 
HPV 
vaccination  
The method 
of using 
qualitative 
synthesis 
within a 
socioecologi
cal 
framework 
enabled 
facilitators 
and barriers 
to 
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ve 
systemat
ic 
review 
and 
evidenc
e 
synthesi
s. BMC 
Public 
Health, 
14, 700. 
doi: 
10.1186
/1471-
2458-
14-700 
vaccination’ 
beliefs were 
unlikely to 
make positive 
HPV vaccine 
decisions; 
evidence 
presented here 
suggests that 
some 
healthcare 
professionals 
avoided 
conversations 
with parents 
about the HPV 
vaccine if they 
perceived this 
to be culturally 
inappropriate. 
be identified 
in relation to 
different 
stakeholders 
Limitations 
Studies not 
published in 
English were 
excluded and 
the findings 
reported 
therefore 
may be 
subject to 
English 
language 
publication  
(Rambo
ut et al., 
2014) 
 
Rambou
t, L., 
None 
mentione
d 
Systemat
ic review 
with data 
analysis 
Sample: 
Twenty-two 
studies 
including 
8079 females 
aged 9–26 
Self-
identified 
barriers and 
facilitators to 
receiving the 
HPV vaccine 
Data 
abstraction 
form was 
developed a 
priori and 
pilot-tested 
Descriptive 
synthesis of 
abstracted 
data was 
completed 
for all 
The most 
commonly 
reported 
facilitators 
were perceived 
benefit of the 
I 
 
 
SR of 
RCT’
s and 
Strengths:   
 First 
systematic 
review to 
isolate views 
of adolescent 
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Tashkan
di, M., 
Hopkins
, L., & 
Tricco, 
A. C. 
(2014). 
Self-
reported 
barriers 
and 
facilitat
ors to 
preventi
ve 
human 
papillo
mavirus 
vaccinat
ion 
among 
adolesce
nt girls 
and 
young 
women: 
A 
systemat
ic 
review. 
Preventi
ve 
Medicin
years in North 
America, 
published 
between 
2008 and 2011 
 
Inclusion 
criteria:  
Qualitative or 
quantitative 
studies of self-
reported 
barriers to the 
HPV vaccine 
in adolescents 
and young 
women age 9-
26 (US & 
Canada only) 
by two  
reviewers. 
Two 
reviewers 
then 
performed all 
data 
abstraction in 
duplicate. 
included 
studies with 
respect to 
study 
characteristic
s, study 
outcome 
results, and 
study 
quality. 
Heterogeneit
y among 
studies 
precluded 
meta-
analysis. 
vaccine and 
receiving a 
recommendatio
n from a 
healthcare 
provider, which 
were each 
reported in six 
of the studies. 
 
endorsement by 
influential 
others, such as 
parents and 
health care 
providers, 
appear to be 
important 
factors in 
prompting 
vaccination 
cohor
t 
studie
s 
girls and 
young 
women with 
respect to the 
acceptability 
of HPV 
vaccination. 
Limitations: 
the pooling 
of data from 
small 
samples of 
participants 
with 
differing 
characteristic
s thus 
limiting the 
ability to 
assess 
whether 
diverse 
interventions 
may be 
needed for 
various 
subgroups of 
young 
females. 
Applicable 
to practice 
setting 
because of  
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e, 58, 
22-32. 
doi: 
10.1016
/j.ypme
d.2013.1
0.009 
 
theme of 
influence of 
endorsement 
by 
healthcare 
provider 
(Hull et 
al., 
2014)  
Hull, P. 
C., 
William
s, E. A., 
Khabele
, D., 
Dean, 
C., 
Bond, 
B., & 
Sanders
on, M. 
(2014). 
HPV 
vaccine 
use 
among 
African 
America
n girls: 
Qualitati
Dissemin
ation of 
Innovatio
ns Theory 
Design: 
cross-
sectional 
observati
onal 
design, 
 
Method: 
Focus 
groups 
and 
interview
s 
 
Sample: 
African 
American 
girls ages 11–
18 (N=34) and 
their mothers 
(N=31), 
broken into 
market 
segments 
based on 
daughter's 
vaccination 
status and 
mother's 
intent to 
vaccinate 
 
Setting: 
convenience 
sampling  
No IV or DV 
because 
qualitative 
study design 
Comprehensi
ve review of 
transcription 
data of focus 
groups and 
interviews 
Four 
research 
assistants 
were trained 
during two 
90-min 
sessions to 
code the 
transcript 
data, 
including 
how to use 
Atlas.ti 
qualitative 
analysis 
software to 
create and 
assign codes 
and extract 
quotes 
Barriers to 
vaccination 
included no 
recommendatio
n from 
healthcare 
professional 
 
Decision 
influencers for 
both mother & 
daughters also 
included a 
provider 
recommendatio
n 
 
Recommendati
ons from 
mothers:  
Message from 
trusted source;  
 Recommend 
together with 
VI Strengths: 
This is the 
first 
published 
study to 
identify 
specific 
market 
segments 
related to 
HPV vaccine 
and to report 
on 
formative 
qualitative 
data aimed at 
comparing 
the 
Undecided 
segment 
to those who 
have 
received or 
rejected the 
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ve 
formativ
e 
research 
using a 
participa
tory 
social 
marketi
ng 
approac
h. 
Gynecol
ogic 
Oncolog
y, 132, 
S13-
S20. 
doi: 
10.1016
/j.ygyno
.2014.01
.046 
other 
preteen 
vaccines; 
Information 
about 
safety/side 
effects; 
Statistics on 
cancer and 
mortality 
vaccine. 
Limitations:  
self-reported 
data and 
convenience 
sampling 
 
Application:  
Data further 
supports the 
influence of 
provider 
recommenda
tion for the 
vaccine  
 
 
 
 
 
 
(Bynum 
et al., 
2014) 
Bynum, 
S. A., 
Staras, 
S. A., 
Malo, T. 
L., 
none 
mentione
d 
Using 
Dillman 
Multi-
phase 
recruitme
nt 
approach: 
Surveys 
mailed 
Physicians 
eligible for 
study 
inclusion 
included those 
who saw 25 or 
more 9- to 17-
year-old girls 
in the past 
Independent 
variables:  
physician 
demographi
cs (age, 
gender, 
practice 
specialty) 
 
5-point 
Likert scales 
were used in 
survey 
Multivariable 
logistic 
regression 
was used to 
model the 
probability of 
recommendin
g 
the HPV 
34% of 
physicians  
recommended 
vaccination for 
girls in the 
early (9-10 
years) 
vaccination age 
group. 
VI Strengths: 
large 
random 
sample size  
 
Limitations: 
data were 
self-
reported, 
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Giuliano
, A. R., 
Shenkm
an, E., & 
Vadapar
ampil, S. 
T. 
(2014). 
Factors 
associate
d With 
Medicai
d 
provider
s' 
recomm
endation 
of the 
HPV 
vaccine 
to low-
income 
adolesce
nt girls. 
J 
Adolesc 
Health, 
54(2), 
190-196. 
doi: 
10.1016/
j.jadohe
alth.201
between 
10/2009 
and 
04/2010 
to a 
random 
sample of 
800 
Florida-
based 
physician
s serving 
Medicaid
-enrolled 
adolescen
ts. Data 
were 
analyzed 
in 2013 
 
A multi-
item 
survey, 
adapted 
from a 
previous 
national 
study 
of HPV 
vaccinati
on among 
physician
s, was 
year and had a 
primary care 
specialty. Of 
the 800 
mailed 
surveys, 485 
were 
completed and 
returned.   Of 
those, 52 did 
not meet 
eligibility 
criteria. The 
final study 
sample 
included 433 
physicians. 
The overall 
response 
rate was 
68.3% 
Dependent 
variables:  
rates of 
recommendi
ng HPV 
vaccine 
vaccine to 
adolescent 
girls aged 9-
17. 
 
All analyses 
were 
conducted in 
2013 using 
SPSS 20.0. 
Statistical 
tests were 
two-tailed, 
with alpha 
level of .05 
and 95% 
confidence 
interval (CI) 
for odds 
ratios (OR). 
74% of 
physicians 
recommended 
vaccination for 
11- to 12-year-
old adolescent 
girls. 
86% of 
physicians 
recommended 
HPV 
vaccination to 
adolescent girls 
aged 13-14. 
Discomfort 
discussing 
STIs with 
parents was 
negatively 
associated with 
HPV vaccine 
recommendatio
n for all 
groups,  
which may 
have 
introduced 
recall and 
reporting 
bias. 
 
Feasibility 
of use in 
practice:  
Results of 
provider 
identified 
barriers can 
be  used to 
aid in 
developmen
t of 
intervention
s to increase 
vaccination 
rates 
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3.08.006 
 
 
used to 
assess 
barriers 
related to 
HPV 
vaccine 
recomme
ndation 
(Bruno 
et al., 
2014) 
Funding: 
NIH/NC
I grant 
 
Bruno, 
D. M., 
Wilson, 
T. E., 
Gany, 
F., & 
Aragone
s, A. 
(2014). 
Identifyi
ng 
human 
papillom
avirus 
vaccinati
on 
practices 
None 
mentione
d 
Cross-
sectional 
survey of 
randomly 
selected 
primary 
care 
providers 
Sample: 552 
providers 
were 
identified and 
a random 
sample of 120 
was generated 
 
64%- Peds. 
19% - 
internists  
17% - family 
practitioners 
 
Setting:  
Brooklyn, 
New York 
between 
November 
2010 and 
January 
2012.  
 
Inclusion 
Independent 
variables: 
Provider 
demographi
cs 
 
Dependent 
variables: 
 
Whether or 
not HPV 
vaccine was 
offered; 
identified 
barriers 
Survey used 
Likert scale 
responses 
Data were 
manually 
entered into 
an access 
database by a 
research 
assistant and 
quality 
control was 
performed by 
the principal 
investigator 
to find and 
address any 
potential data 
entry 
problem.  
 
Analysis was 
performed 
using IBM 
SPSS 
Statistics® 
ver- 
34%of 
respondents 
reported that 
they routinely 
offered HPV 
vaccine to their 
eligible 
patients. 70% 
of physicians 
reported that 
the lack of 
preventive care 
visits for 
patients in the 
eligible age 
group limited 
their ability 
to recommend 
the HPV 
vaccine and 
70% of those 
who reported 
this barrier do 
not routinely 
VI Strengths: 
identifies 
several 
potential 
opportunitie
s for 
intervention
s that could 
lead to 
increased 
HPV 
vaccination. 
  
Limitations: 
Results are 
all self-
reported, so 
possibility 
that 
respondents 
reported 
socially 
desirable 
responses. 
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among 
primary 
care 
provider
s of 
minority
, low-
income 
and 
immigra
nt 
patient 
populati
ons. 
Vaccine, 
32(33), 
4149-
4154. 
doi: 
10.1016/
j.vaccine
.2014.05
.058 
criteria: 
pediatricians, 
family prac- 
titioners, and 
internal 
medicine 
physicians 
serving 
neighborhood
s 
identified 
from the 
American 
Community 
Survey  as 
having 
large minority 
populations 
(greater than 
30%) and 
higher than 
the average 
rates of HPV 
related cancer 
cases 
according to 
the New York 
State Cancer 
Registry 
sion 19. recommend 
HPV vaccine. 
 most common 
barrier 
impeding them 
from offering 
the vaccine 
was lack of 
time to 
educate parents 
or patients 
(66%). 
 
Feasibility 
of use in  
practice:  
Using the 
identified 
barrier of 
not enough 
time to 
educate 
parents/pati
ents can 
assist with 
intervention
s to increase 
patient 
education 
(i.e. the 
CDC HPV 
fact sheet 
for parents) 
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(Thomas 
et al., 
2013) 
 
Funding: 
Robert 
Wood 
Johnson 
Foundati
on 
 
Thomas, 
T. L., 
Stricklan
d, O., 
Dicleme
nte, R., 
& 
Higgins, 
M. 
(2013). 
An 
opportun
ity for 
cancer 
preventi
on 
during 
preadole
scence 
and 
adolesce
nce: 
Health 
Belief 
Model 
(HBM) 
Descripti
ve cross-
sectional 
design 
Method: 
surveys, 
and 
quantitati
ve 
analysis. 
Sample: 519 
subjects (35% 
response rate)  
Inclusion 
criteria:  
parent or 
primary 
caregiver 
responsible 
for girls or 
boys aged 9 to 
13 years; had 
to reside in the 
counties of 
interest, speak 
and read 
English, and 
be at least 18 
years of age. 
Independent 
variables:  4 
constructs of 
the HBM 
Perceived 
vulnerability
, perceived 
severity, 
perceived 
benefits, 
perceived 
barriers 
 
Dependent 
variables: 
Intent to 
vaccinate or 
not 
vaccinate 
Likert scales Descriptive 
statistics 
were 
calculated for 
all variables 
 
t tests and 
analysis of 
variance F 
tests for all 
continuous 
variables and 
c2 tests for 
all 
categorical 
variables.  
343 (66.1%) 
indicated that 
they will not or 
had not 
vaccinated 
their child, 
169 (32.6%) 
indicated that 
they will or 
had vaccinated 
their child, and 
7 (1.3%) did 
not respond to 
this question. 
Focusing on 
perceived 
barriers and 
benefits and on 
parents’ level 
of knowledge 
about HPV, 
healthcare 
providers can 
have frank 
conversations 
with parents in 
order to 
facilitate the 
parents’ 
informed 
decision 
making. 
VI Strengths:   
Large 
sample 
cohort study 
with 
focused 
rural parent 
population 
 
Limitations: 
Very low 
response 
rate with 
telephone 
survey 
method, so 
methods 
were 
changed to 
paper & 
pencil & 
face to face 
to increase 
response 
rates. 
Feasibility 
of use in 
practice:  
This study 
is 
particularly 
useful for 
providers in 
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stopping 
human 
papillom
avirus 
(HPV)-
related 
cancer 
through 
HPV 
vaccinati
on. J 
Adolesc 
Health, 
52(5 
Suppl), 
S60-68. 
doi: 
10.1016/
j.jadohe
alth.201
2.08.011 
 
a rural 
practice 
setting to 
provide a 
framework 
from which 
to design 
intervention
s  to 
increase 
rates of 
HPV 
vaccination 
CDC 
NIS data 
2013 
Retrieve
d from: 
http://w
ww.cdc.
gov/vacc
ines/who
/teens/va
 Design:  
The NIS-
Teen is a 
random-
digit-
dialed 
telephone 
survey of 
parents 
and 
Sample: 6,039 
by landline 
(59.5%) and 
12,225 by cell 
phone 
(54.5%) had 
adequate 
provider data 
 
 
Independent 
variables: 
Demographi
cs (age, 
gender, 
ethnicity, 
income-
level, 
insurance 
coverage) 
  Nationwide 
HPV vaccine 
rates: 
1-dose= 57% 
2-doses=47% 
3-does=37% 
 
Kentucky’s 
rates: 
1-dose= 47% 
NA Strengths:   
Large 
sample 
national 
survey with 
provider 
verified 
vaccine data 
included 
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ccinatio
n-
coverage
.html 
 
http://w
ww.cdc.
gov/mm
wr/previ
ew/mm
wrhtml/
mm6329
a4.htm?s
_cid=m
m6329a
4_w#tab
3 
 
guardians 
of teens 
13–17 
years old; 
in 2013, 
it 
included 
data for 
more than 
18,000 
adolescen
ts. The 
telephone 
survey is 
followed 
by 
collection 
of 
vaccinati
on 
records 
from 
clinicians
. 
Method: 
random 
digit dial 
(RDD) 
list-
assisted 
landline 
and cell-
phone 
 
 
 
 
Dependent 
variables: 
Provider 
verified 
rates of 
vaccination 
from 2013 
 
Parental 
reasons for 
not 
vaccinating 
 
 
2-doses=38% 
3-does=26% 
 
Top 5 reasons 
parents did not 
initiate 
vaccine: 
Lack of 
knowledge= 
15.5% 
Not necessary= 
14.7% 
Safety 
concerns= 
14.2% 
Not 
recommended
= 
13% 
Not sexually 
active=11.3% 
 
Weaknesses
:  response 
rates may 
mean 
incomplete 
data   
 
 
Implications 
Kentucky is 
nearly 10% 
points 
below the 
national 
level  
 
NO 
provider 
recommend
ation is 4
th
 
out of 5 on 
the list of 
barriers at 
13% 
reported 
USE OF THE AFIX MODEL TO IMPROVE ADOLESCENT HPV 
 
35 
 
sample 
frame 
CDC 
HPV 
statistics 
Retrieve
d from: 
http://w
ww.cdc.
gov/canc
er/hpv/st
atistics/s
tate/cerv
ical.htm 
 
  Data from 
population-
based cancer 
registries 
participating 
in the CDC’s 
supported 
National 
Program of 
Cancer 
Registries or 
NCI’s -
supported 
Surveillance, 
Epidemiology, 
and End 
Results 
Program, 
includes all 
states meeting 
USCS 
publication 
criteria for all 
years 2006–
2010 and 
covers 
approximately 
94.8% of the 
U.S. 
population. 
   Incidence of 
HPV in 
Kentucky 8.04-
9.54 per 
100,000 
 
Nationwide 
rates are 
 
 
 
 
 
 
  
NA Implications
: 
KY ranks in 
the highest 
tier of 
cervical 
cancer rates 
in the US, 
so programs 
to increase 
HPV 
vaccine 
rates are 
validated 
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(Jeudin 
et al., 
2014) 
ACS 
grant 
Jeudin, 
P., 
Liverigh
t, E., del 
Carmen, 
M. G., 
& 
Perkins, 
R. B. 
(2014). 
Race, 
Ethnicit
y, and 
Income 
Factors 
Impacti
ng 
Human 
Papillo
mavirus 
Vaccina
tion 
rates. 
Clinical 
Therape
utics, 
36(1), 
24-37. 
None 
mentione
d 
Systemat
ic review 
of 124 
reference
s ( NIS 
data, 
RCT’s) 
Sample:  
relevant 
English-
language 
literature (124 
sources) to 
identify 
current 
vaccination 
rates and 
factors 
associated 
with vaccine 
uptake. 
Independent 
variables: 
age, gender, 
ethnicity 
Dependent 
variables:  
rates of 
vaccine 
initiation and 
completion;  
barriers and 
facilitators to 
vaccination 
Systematic 
review of 
data 
pertaining to 
outcomes of 
HPV vaccine 
rates, and 
identified 
barriers and 
facilitators 
HPV 
vaccination 
recommenda
tion by a 
health care 
provider has 
been shown 
to increase 
the 
likelihood of 
vaccination 
up to 18-fold 
(95% CI, 1–
23) and up to 
90% of 
females who 
report 
vaccination 
also report 
provider 
recommenda
tion. 
Provider 
recommendatio
n is a key factor 
in HPV 
vaccination, 
and minorities 
are less likely 
to report 
receiving 
recommendatio
ns for HPV 
vaccination;  
desire to 
prevent cancer 
was also a key 
factor in 
vaccination 
rates 
I Strengths:  
Systematic 
review of 
124 
references 
by 4 
physicians 
from Boston 
University 
and Harvard 
Limitations:  
The exact 
methods of 
data 
extraction, 
analysis and 
synthesis 
were not 
described by 
the authors 
Feasibility 
of use in 
practice: 
Because 
provider 
recommend- 
tion is 
crucial to 
vaccine 
uptake, and 
each 
provider 
interacts 
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doi: 
10.1016
/j.clinth
era.2013
.11.001 
 
with 
hundreds to 
thousands of 
patients, 
interventions 
targeting 
providers 
such as 
academic 
detailing or 
performance
-
improvement 
continuing 
medical 
education 
may be 
effective 
ways to 
improve 
vaccination 
rates. 
(Gilkey, 
Dayton, 
et al., 
2014b) 
Gilkey, 
M. B., 
Dayton, 
A. M., 
Moss, J. 
L., 
CDC’s 
AFIX 
model for 
improvin
g 
vaccinatio
n rates 
Randomi
zed-
controlle
d trial 
Sample:  
randomly 
assigned 91 
primary care 
clinics in 
North 
Carolina, 
serving 
107,443 
adolescents, to 
Independent 
variables: 
 
IV1 = in-
person AFIX 
consultation 
IV2 = 
webinar 
consultation 
IV3 = no 
Primary 
study 
outcome was 
5- 
month 
coverage 
change for 
Tdap, 
meningococc
al vaccine, 
x2 (Chi-
squared) 
tests and 
analysis of 
variance 
models were 
used.  To 
analyze 
intervention 
effects at the 
Among 
adolescents 
ages 11 to 12 
years, 
AFIX 
consultations 
increased 
coverage 
for the 3 
vaccines in the 
II Strengths:  
statistical 
significance 
found at the 
5-month 
follow-up in 
the 2 
intervention 
arms 
 
USE OF THE AFIX MODEL TO IMPROVE ADOLESCENT HPV 
 
38 
 
Sparks, 
A. C., 
Grimsha
w, A. 
H., 
Bowling
, J. M., 
& 
Brewer, 
N. T. 
(2014). 
Increasi
ng 
Provisio
n of 
Adolesc
ent 
Vaccine
s in 
Primary 
Care: A 
Random
ized 
Controll
ed Trial. 
Pediatri
cs, 
134(2), 
E346-
E353. 
doi: 
10.1542
/peds.20
receive 
 1. no 
consultation 2. 
an in-person 
or 3. webinar 
AFIX 
consultation. 
 
Inclusion 
criteria:  
pediatric and 
family 
practice 
clinics with 
 > 200 patients 
ages 11 to 
18 years with 
active records 
in the registry; 
consultation 
 
Dependent 
variables: 
 
Rates of 
adolescent 
vaccinations 
at 5 mo. 
Follow-up 
and at 1 year 
and HPV 
vaccine 
initiation 
(>1dose, 
female 
patients 
only); also 
analyzed 
coverage 
changes for 
other 
vaccines at 5 
months and 
for all 
outcomes at 
1 year. 
level of the 
patient, 
authors 
performed 
mixed-level 
Poisson 
regres- 
sions for 
each 
vaccine, 
modeling the 
change in 
vaccine 
coverage 
between 
baseline and 
follow-up for 
each age 
group. 
adolescent 
platform at 5 
months 
In-person arm 
rate increases: 
 
Tdap   (3.4%) 
MCV   (4.7%) 
HPV    (1.5%) 
 
Webinar arm:  
Tdap   (3.6%) 
MCV   (4.4%) 
HPV    (1.9%) 
 
 
adolescents  13 
to 18 years, 
AFIX 
consultations 
increased 
vaccine 
coverage at 5 
months only for 
the in-person 
versus control 
arms for HPV 
vaccine series 
completion 
(0.7%). 
Limitations:  
no statistical 
significance 
found in 
intervention 
arms at 1-
year  
 may 
indicate 
that vaccine 
providers in 
the 
intervention 
arms were 
able to 
initiate, 
but not 
sustain, 
quality 
improvement 
efforts 
 
Feasibility 
of use in 
practice:  
This study 
has direct 
correlation 
to support 
program 
planning 
using the 
AFIX model  
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13-4257 
 
(Reiter 
et al., 
2014) 
secondary 
data 
analysis 
of 
publicly 
available 
data from 
the NIS-
Teen 
analyzed 
provider-
verified 
vaccinati
on data 
from the 
2010–
2011 
National 
Immuniz
ation 
Survey-
Teen for 
Hispanic 
females 
ages 13 
to 17 
years (n 
=2,786). 
 
 
 
 
 
 
 
Sample: 
Hispanic 
adolescent 
females age 
13-17; N= 
2786 
 
Setting:  2010-
2011 NIS data 
from the CDC 
Independent 
variables: 
ethnicity, 
age & 
gender 
Dependent 
variables:  
rates of 
vaccination;  
determinants 
of 
vaccination 
Rates of 
vaccination  
as reported 
by the NIS 
data 
 
Correlates of 
HPV 
vaccination 
identified in 
NIS data 
weighted 
logistic 
regression to 
identify 
correlates of 
HPV vaccine 
initiation 
Healthcare 
provider 
recommendatio
n was one of 
the 
key 
determinants of 
HPV 
vaccination 
among 
Hispanic 
adolescent 
females. HPV 
vaccine 
initiation was 
60.9%, 
completion was 
36.0%, and 
follow-through 
was 59.1%. 
Initiation 
and completion 
were more 
common 
among older 
daughters and 
IV Strengths = 
large cohort 
(2736) of 
respondents 
 
Limitations 
= focused on 
Hispanic 
population  
 
 Applicable 
to practice 
setting 
because 
provider 
recommenda
tion was 
again an 
identified 
key 
determinant 
to HPV 
vaccine 
initiation 
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 those whose 
parents had 
received a 
provider 
recommendatio
n to vaccinate 
(all P < 0.05). 
Spanish-
speaking 
parents were 
more likely 
to indicate lack 
of provider 
recommendatio
n (20.2% vs. 
5.3%) 
 
**(Moss
, Reiter, 
Dayton, 
& 
Brewer, 
2012b) 
Moss, J. 
L., 
Reiter, 
P. L., 
Dayton, 
A., & 
Brewer, 
N. T. 
(2012a). 
 
CDC’s 
AFIX 
model 
 
 
 
 
 
 
 
 
 
 
 
 
A one-
month 
immuniz
ation 
competiti
on 
among 
federally 
qualified 
health 
centers,  
during 
April 
2010. 
Participat
ion was 
clinical 
coordinators 
from 17 
federally 
qualified 
health centers 
(serving 7827 
patients ages 
12–17) in 
North 
Carolina 
participated in 
a competition 
to increase 
uptake of  
adolescent 
Rates of 
recommende
d adolescent 
vaccines: 
tetanus, 
diphtheria, 
and pertussis 
booster; 
meningococc
al conjugate; 
and human 
papillomavir
us. 
Rates of 
adolescent 
vaccine 
coverage  
Data 
analyses 
used SAS 
Version 9.2 
(Cary, NC). 
Statistical 
tests were 
two-tailed 
with a 
critical alpha 
of .05. 
Vaccine uptake 
increased over 
the one-month 
follow-up 
period 
(p < .001, 
Table 2). Prior 
to the 
intervention, 
31.1% (IQR, 
13–33%) 
of each clinic’s 
adolescent 
population was 
up-to-date on 
targeted 
VII  Strengths: 
A strength of 
this 
study is the 
use of web-
based 
technology 
to administer 
the AFIX. 
intervention 
components. 
While 
studies have 
shown that 
the AFIX 
program has 
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Increasi
ng 
adolesce
nt 
immuni
zation 
by 
webinar: 
A brief 
provider 
interven
tion at 
federall
y 
qualifie
d health 
centers. 
Vaccine, 
30(33), 
4960-
4963. 
doi: 
10.1016
/j.vaccin
e.2012.0
5.042 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
open to 
all of the 
131 
federally 
qualified 
health 
centers 
in the 
state, and 
18 
clinics 
opted to 
participat
e in an 
AFIX 
webinar 
 
 
 
vaccines 
 
and non-
targeted 
vaccines, while 
after the 
intervention, 
32.2% (IQR, 
14–34%) was 
up-to-date 
(Chi-square = 
27.34, p < 
.001). 
 
relatively 
low costs], 
employing 
webinars and 
emails 
reduces the 
costs 
associated 
with in-
person visits. 
 
Limitations: 
did not have 
a control 
arm, as 
this would 
not have 
been 
acceptable to 
the 
community 
partners; 
however, the 
use of an 
instrumental 
comparison 
(non-
targeted 
vaccines) 
allowed 
authors to 
treat clinics 
as their own 
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controls. 
 
**(LeBa
ron et 
al., 
1999b) 
LeBaron
, C. W., 
Mercer, 
J. T., 
Massou
di, M. 
S., Dini, 
E., 
Stevens
on, J., 
Fischer, 
W. M., . 
. . 
DesVig
nes-
Kendric
k, M. 
(1999). 
Changes 
in clinic 
vaccinat
AFIX 
model 
Retrospe
ctive 
examinat
ion of 
clinic 
vaccinati
on 
coverage 
data 
 
Children aged 
19 to 35 
months 
enrolled in 
clinics in 
localities that 
had applied 
the 
intervention 
for 4 years or 
longer. 
Four states 
and 2 cities 
that had 
applied the 
AFIX 
intervention 
for 4 years 
or longer 
were 
identified. 
The number 
of clinic 
records 
reviewed 
annually was 
4639 to 
18,000 in 73 
to 116 
clinics for 
states, and 
714 to 5276 
in 8 to 25 
clinics for 
cities. 
Change in 
median clinic 
coverage 
rates, based 
on the 
primary (4-3-
1) vaccine 
series, with 
comparison 
to results of 
the National 
Immunizatio
n Survey. 
Authors used 
same method 
as in Georgia 
 
Distribution 
plot by rank 
ordering all 
clinics in a 
locality by 
coverage 
rate, plotting 
this 
distribution 
in deciles 
and 
determining 
the median 
Median clinic 
coverage rose 
in all localities: 
Missouri, 44% 
(1992) to 93% 
(1997); 
Louisiana, 61% 
(1992) to 83% 
(1997); 
Colorado, 55% 
(1993) to 75% 
(1997); Iowa, 
71% (1994) to 
89% (1997); 
Boston, Mass, 
41% (1994) to 
79% (1997); 
and Houston, 
Tex, 28% 
(1994) to 84% 
(1997). The 
increase in 
clinic coverage 
exceeded that 
of the general 
population in 5 
IV  Strengths:  
Average 
vaccine rate 
increase of 
5% over 4-
years was 
very close to 
the 6% 
increase seen 
in the 
Georgia state  
7 year study.  
Demonstrate
s 
reproducibili
ty of positive 
effects 
 
 
Limitations:  
the clinics 
measured 
began 
collecting 
vaccination 
data and 
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ion 
coverag
e after 
instituti
on of 
measure
ment 
and 
feedbac
k in 4 
states 
and 2 
cities. 
Archives 
of 
Pediatri
cs & 
Adolesc
ent 
Medicin
e, 
153(8), 
879-
886. 
 
 
localities and 
was identical in 
the sixth. The 
average annual 
coverage rise 
attributable to 
the intervention 
was +5 
percentage 
points per year 
(Georgia, +6 
per year). 
using the 
AFIX model 
before the 
federal 
mandate was 
in place, so 
had an 
established 
protocol 
 
Applicable 
to practice 
setting 
because 
shows clear 
vaccination 
rate increase 
using the 
AFIX 
program 
 
**(LeBaron 
et al., 1997) 
LeBaron, C. 
W., Chaney, 
M., 
Baughman, 
A. L., Dini, 
E. F., Maes, 
E., Dietz, 
V., & 
Bernier, R. 
(1997). 
Impact of 
measuremen
t and 
feedback on 
vaccination 
coverage in 
public 
clinics, 
1988-1994. 
Jama, 
277(8), 631-
635.  
 
None 
mentioned 
Examina
tion of 
data 
from 
Georgia 
public 
clinics, 
doses-
administ
ered 
records, 
and 
National 
Health 
Intervie
w 
Surveys. 
 
ITS 
based 
Children 
attending 
Georgia 
public clinics. 
Vaccination 
coverage 
rates 
For the 
period 1988 
through 
1994, 136 
004 Georgia 
public clinic 
vaccination 
records for 
children 21 
to 23 months 
of age were 
reviewed. 
Basic 
statistical 
analysis 
(medians, 
ranges) 
Median series-
completion 
rates at public 
clinics rose 
from 53% to 
89%, while 
indexes of 
under-
vaccination 
fell: missed 
opportunities 
for 
simultaneous 
vaccination 
(6% to 0%), 
lost contact for 
more than 12 
months (14% to 
1%), and first 
vaccination 
more than 1 
month late 
(19% to 8%) 
In 1988, 
vaccination 
coverage of 
children 24 
months of age 
in the National 
Health 
Interview 
Survey (NHIS) 
was 53%, 
identical to 
median public 
clinic coverage 
in Georgia; in 
1993, NHIS 
coverage was 
60%, while 
median public 
clinic coverage 
in Georgia was 
90%, 
suggesting that 
IV  Study 
shows 
widespread 
application 
of the AFIX 
program 
with 
measurable 
increases in 
vaccination 
rates 
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**(Perkins, 
2014) 
 
Perkins, R. 
B., Zisblatt, 
L,  Legler, 
A., Trucks, 
E., 
Hanchate, 
A.and  
Gorin, S.S. 
(2014). 
Effectivenes
s of a 
provider-
focused 
intervention 
to improve 
HPV 
vaccination 
rates in boys 
and girls,. 
Vaccine, In 
press.  
 
 
None 
mentioned 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCT 
 
Provider
-focused 
intervent
ion that 
included 
repeated 
contacts, 
educatio
n, 
individu
alized 
feedbac
k, and 
strong 
quality 
improve
ment 
incentiv
es to 
raise 
HPV 
vaccinat
ion rates 
at two 
federally 
qualified 
commun
ity 
health 
centers. 
 
Sample:  13, 
118 eligible 
patients from 
8 clinics 
 
2 clinics and 
4093 patients 
randomly 
chosen for 
intervention 
arm 
 
Control arm 
was remaining 
6 clinics with 
9025 eligible 
patients 
 
 Assessment 
of baseline 
HPV vaccine 
rate 
 
Independent 
variable:  
Intervention 
arm or non-
intervention 
arm 
 
Dependent 
variable: 
 Number 
initiating 
HPV vaccine 
and 
completing 
subsequent 
dose due 
HPV 
Vaccination 
rates of 
patients age 
11-21 
multivariable 
logistic 
regression, 
controlling 
for clustering 
by practice 
 
All analyses 
were 
performed 
using Stata 
Version 
10.1. 
During the 
active period, 
girls at 
intervention 
practices were 
more likely to 
initiate HPV 
vaccination 
than those at 
control 
practices (OR 
1.6 95% CI 
1.1–2.2), , 
differences 
between 
intervention 
and control 
practices did 
not remain 
significant in 
the post-
intervention 
period.  
 
For vaccine-
naïve boys, the 
odds of 
initiating HPV 
vaccination 
were similar at 
intervention 
and control 
practices in the 
II Strengths: 
this study 
demonstrates 
the ability of 
a provider-
centered 
multi-
component 
PI CME 
intervention 
to create 
sustained 
improvemen
t in HPV 
vaccination 
rates. All 
practices 
improved 
over time, 
especially 
for boys, but 
intervention 
practices 
demonstrate
d 
improvemen
ts beyond 
those seen in 
control 
practices 
 
Limitations: 
The dramatic 
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Interven
tions 
included 
six to 
eight 
sessions 
conduct
ed over 
approxi
mately 
12 
months. 
 
 
 
pre-
intervention 
period. The 
odds of vaccine 
initiation 
among boys at 
intervention 
compared to 
control 
practices rose 
to 11 (95% CI 
6.9–18) in the 
transition 
period, 11 
(95% CI 6.9–
17) in the 
active period, 
and remained 
elevated at 8.5 
(95% CI 5.2–
14) in the post-
intervention 
period 
 
improvemen
ts in HPV 
vaccination 
rates for 
boys were 
catalyzed by 
the 
availability 
of state-
funded HPV 
vaccine for 
boys during 
the transition 
period, 
making the 
effects of the 
intervention 
difficult to 
distinguish 
from the 
effects of 
increased 
vaccine 
availability 
 
Applicability 
to practice:  
The authors 
utilized the 
AFIX model 
for their 
intervention 
and achieved 
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Key Terms and Abbreviations: 
AFIX = Assessment, Feedback, Information and Exchange  
CDC = Centers for Disease Control 
CI = Confidence Interval 
DV = Dependent variable 
HPV = Human Papillomavirus 
IV = Independent variable 
ITS = Interrupted time series study 
MCV = Meningicoccal vaccine 
NIS = National Immunization Survey 
RCT = Randomized controlled trial 
SR = Systematic review 
Tdap = Tetanus, diptheria and pertussis vaccine 
measurable 
improvemen
ts in HPV 
vaccine rates 
in a large 
population 
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Table 7. Level of Evidence Synthesis Table 
  
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
 
11 
 
12 
 
13 
 
Level I: Systematic 
review (SR) or meta-
analysis 
 
X 
 
X 
           
Level II:  
Randomized 
Controlled Trial 
(RCT) 
   
X 
 
X 
         
Level III: Controlled 
trial without 
randomization 
             
Level IV: Case-
control or cohort 
study 
     
X 
 
X 
 
X 
      
Level V:  SR of 
qualitative or 
descriptive studies 
        
X 
     
Level VI: 
Qualitative or 
descriptive study 
         
X 
 
X 
 
X 
 
X 
 
Level VII:  Expert 
opinion or consensus 
             
X 
 
Key to Synthesis table 
1 - (Jeudin et al., 2014) 2 - (Rambout et al., 2014) 3 - (Gilkey, Dayton, et al., 2014b) 4 - (Perkins, 2014) 
5 - (LeBaron et al., 1997) 6 - (LeBaron et al., 1999b) 7 - (Reiter et al., 2014) 8 - (Ferrer et al., 2014) 
9 - (Bruno et al., 2014) 10 - (Bynum et al., 2014) 11 - (Hull et al., 2014) 12 - (Thomas et al., 2013)  13 - (Moss et al., 2012a) 
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Table 8. Evaluation Methods  
Evaluation 
Methods  
Measures 
(Level of 
Measure) 
Data 
Source 
Data 
Collection 
Plan 
Timeline Type of 
Evaluation 
Type of 
Data 
Analysis 
 
Objective 1 
To increase 
numbers of 
HPV 
vaccination 
among 
adolescents 
11-17   
Proportion 
of HPV 
vaccination 
in 11-17 
year olds  
(count) 
EMR 
Query 
Pre - 
intervention 
Baseline 
rates 
(December 
2015-
February 
2016) 
Outcome Chi-square 
analysis 
 
Specific 
Aim 1: 
80% of 
providers 
utilize 
CDC rubric 
when 
presenting 
the HPV 
vaccine 
Number of 
provider 
respondents 
indicating 
regular use 
of CDC 
rubric 
(count) 
 
Provider 
Survey 
Pre- and  
post-
intervention 
survey 
 
December, 
2016 – 
February 
2017 
Process 
 
Percentages 
& 
frequencies 
Chi-
squared 
analysis 
Specific 
Aim 2: 
80% of 
adolescents 
initiate 3 
dose HPV 
series. 
Proportion 
of HPV 
vaccination 
in 11-17 
year olds  
(count) 
EMR 
Query 
Post-
intervention 
Post 
Intervention 
rates 
(December 
2016 – 
February 
2017) 
Outcome  Chi-square 
analysis 
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Appendix A.  Chart Audit Tool 
 
Study number:_______________ 
Gender:_____________________ 
Age:________________________ 
Race:_______________________ 
Insurance:___________________ 
 
 
 
At the patient’s 11-17 year old well-child visit, were the following documented: 
 
 
Information Yes No Comments 
Was counseling 
on the HPV 
vaccine provided? 
 
 
By: ___ CMA 
      ____NP/MD 
  
Was the HPV 
vaccine offered? 
 
   
Patient’s response 
if vaccine was 
offered 
__ Accepted 
__ Deferred 
__ Declined 
  
Was the HPV 
vaccine series 
initiated? 
   
Was the vaccine 
series initiated or 
completed prior 
to this visit? 
   
Were the other 
ACIP 
recommended 
vaccines (Tdap & 
MCV) given?  
   
 
Doses given (Y/N)? #1_________  #2__________  #3___________ 
           On-time?    Y/N  Y/N  Y/N 
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Appendix B. Provider Survey/Questionnaire  
Please answer the following questions by selecting the answer that best represents your experience as a provider: 
1.  How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old FEMALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
2.    How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old MALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
3.  When offered, what percentage of your FEMALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
4.  When offered, what percentage of your MALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  Please select 
all that apply: 
Practice Facilitators Practice Barriers 
 My practice participates in the Vaccines 
for Children (VFC) program. 
 The HPV vaccine is not stocked or there is low 
availability in my practice. 
 My clinic has reminders within the 
EMR for HPV vaccination. 
 My practice is not adequately reimbursed for HPV 
vaccine administration. 
 My clinic uses a form during well-child 
exams that prompts for CDC 
recommended vaccinations. 
 I do not have time to discuss HPV vaccination 
during patient visits. 
 I have time to educate my patients about 
HPV and the vaccine. 
Other: 
Other:  
 
 
  Continued on next page…… 
Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  Please select 
all that apply: 
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Provider Facilitators Provider Barriers 
 I strongly recommend the HPV vaccine 
to all eligible patients. 
 I have concerns about the long-term safety of the 
HPV vaccine. 
 I have completed continuing education 
regarding HPV and/or the HPV vaccine. 
 I feel uncomfortable discussing a vaccine for a 
sexually transmitted infection with my patients 
and/or their parents. 
 I am aware of the CDC/ACIP 
recommendations for HPV vaccination. 
 I do not agree with the CDC/ACIP 
recommendations for HPV vaccination. 
Other:  
 
Other: 
  
Patient Facilitators Patient Barriers 
 My patients have a good understanding 
of the risks of HPV infection. 
 My patients are unaware of the risks of HPV 
infection. 
 My patients/their parents believe that 
they are at risk for HPV. 
 My patients think the cost of the HPV vaccine is too 
high. 
 My patients have a belief in primary 
prevention. 
 My patients are worried about the long-term safety 
of the HPV vaccine. 
 My patients are aware of the Vaccines 
for Children (VFC) program and its 
coverage. 
 My patients are unlikely to return for the 2
nd
 and 
3
rd
 dose of the vaccine series. 
 My patients have positive peer/family 
support regarding HPV vaccination. 
 My patients are unlikely to get the vaccine because 
it is not required for school entry. 
Other:   My patients are concerned about the pain 
associated with the HPV vaccine. 
Other: 
 
 
Please answer the following questions about the CDC/ACIP recommendations for HPV vaccination to the best of 
your knowledge: 
8.  What is the recommended interval for HPV vaccination? Check all that apply 
a.  0, 3, and 6 months   
b.  0, 1-2, and 6 months 
c.  0, and 6-12 months 
d.  0, 6, and 9 months 
 
 
          Continued on next page…  
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9.  What is the ideal age of vaccination for males and females? 
a.  ages 11-12, can be given as early as 9 
b.  ages 13-15, can be given as early as 11 
c.  ages 9-13, can be given as early as 9 
d.  ages 15-18, can be given as early as 9 
10. What are the recommendations for catch-up vaccination for males and females? 
a.  Catch-up for unvaccinated men and women ages 13-18. 
b.  Catch-up for unvaccinated men and women ages 13-21. 
c.  Catch-up for unvaccinated men ages 13-21 (and up to 26 for special populations), catch-up for women 13-26. 
d.  Catch-up for unvaccinated men ages 15-21 (and up to 26 for special populations), catch-up for women 15-26. 
 
 
Comments: Please feel free to share any comments or ideas you have related to the HPV vaccine 
recommendations for 11-12 year olds in your clinic…   
 
 
 
 
 
 
 
 
 
 
THANK YOU FOR PARTICIPATING! 
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Appendix C.  CDC slide set on HPV vaccine 
 
  
You	are	the	Key	
to	HPV	Cancer	Preven on	
Understanding	the	Burden	of	HPV	Disease,		
the	Importance	of	the	HPV	Vaccine	Recommenda on,		
and	Successfully	Communica ng	about	HPV	Vaccina on	
Emily	Messerli	
DNP	candidate	
University	of	Kentucky	College	of	Nursing	
	December2016	
	
{Updated	Nov	18,	2015)	
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Appendix D. Provider talking tips rubric 
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Appendix E – proposed 5th grade school letter with 6th grade health requirements (Principal) 
Dear Parent/Guardian, Your student will be enrolling in the 6th grade next year and will need the following 
on file prior to starting school. Per 902 KAR 2:060 a student cannot attend school without this 
documentation.  
1. A school Physical Examination is required for 6th grade entry.  
 
(Done within one calendar year of enrollment. The KHSAA Sports Physical Form & Consent is a different 
form and cannot be substituted.)  
 
2. A current, updated Kentucky Immunization Certificate, including all previously required 
immunizations and the following 6th grade requirements.  
 
* One dose of Tdap regardless of interval since last dose of Tetanus-containing vaccine will be required 
for students at 6th grade entry, with option of Td for individuals who cannot receive Pertussis-containing 
vaccine.  
 
* Two (2) doses Varicella or proof of history of Chicken Pox. (Proof of Chicken Pox (Varicella) disease in 
lieu of immunization must now be in the form of a diagnosis of typical Varicella disease or verification of a 
history of Varicella disease or Herpes Zoster disease by a healthcare provider.)  
 
* One dose of Meningococcal vaccine (MCV) for 6th grade entry. The use of Meningococcal Conjugate 
Vaccine is preferred, but Meningococcal Polysaccharide Vaccine (MPSV) may be used if the conjugate 
vaccine is unavailable.  
 
6
th
 grade recommended vaccines: 
• HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and 
other diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to 
protect against these serious diseases. Your preteen should receive the second dose 6-12 months after 
the first dose. 
 
3. If your student is going to play sports in middle school, they will need a KHSAA Sports Physical Form 
& Consent completed by you and your Healthcare Provider. The form is available online through 
www.fcps.net  
 
Please return your student’s forms as soon as you’ve had the appointment with your Healthcare Provider. 
If you complete these requirements over the summer, please bring the forms to your student’s middle 
school prior to the first day of school.  
 
Thanks for your help with getting your student’s required 6th grade documentation turned in.  
 
 
 
_______________________  
School Principal            Date  
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Appendix F. School Nurse Letter 
 
[INSERT NURSE NAME], School Nurse 
[INSERT SCHOOL ADDRESS] 
 
[INSERT CURRENT DATE] 
 
Dear Parent or Guardian: 
 
As your child’s school nurse, I want to remind you of the importance of getting your son or daughter 
vaccinated before they go back to school this fall. Vaccines are the best way you can protect your child 
from a number of serious diseases, including cancers caused by HPV. 
 
As you are making your back-to-school checklist for your preteen, I encourage you to make sure your 
sons and daughters get all the vaccines that are recommended for them. Schedule your child’s 
appointment today to ensure they are up-to-date on the vaccines they need. The Centers for Disease 
Control and Prevention (CDC) and the Advisory Committee on Immunization Practices recommend your 
son or daughter receive the following vaccines: 
 Quadrivalent meningococcal conjugate vaccine is recommended for preteens at age 11 or 12 for 
protection against bacteria that cause meningococcal disease, a very serious illness which can 
lead to death in as little as 48 hours. A second shot is recommended for teens at age 16 to 
continue providing protection. 
 HPV vaccine is recommended for preteens at age 11 or 12 to protect against cancers and other 
diseases caused by HPV infection. Both boys and girls should receive 2 doses of HPV vaccine to 
protect against these serious diseases. Your preteen should receive the second dose 6-12 
months after the first dose. 
 One dose of Tdap vaccine is recommended for preteens at age 11 or 12 to continue providing 
protection against tetanus, diphtheria, and pertussis (whooping cough). 
 Preteens and teens should also get the flu vaccine every year, ideally as soon as the vaccine is 
available.  
 
Kentucky requires Meningococcal and Tdap for school entry; to learn more about state immunization 
requirements, go to: www.immunize.org/laws. 
 
Protect your preteen and talk with your child’s clinician about what vaccines they need. You may also 
contact me with any questions. I can be reached at [PHONE NUMBER] and I am in my office [INSERT 
OFFICE HOURS FOR VISITS].  I can also provide you with additional resources about vaccination and 
other health topics for the preteen and teen years. To learn more about adolescent vaccines, please visit 
CDC’s Vaccines for Preteens and Teens website at www.cdc.gov/vaccines/teens. 
 
Sincerely,  
[INSERT NAME OF SCHOOL NURSE]  
Your School Nurse 
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